期刊
FRONTIERS IN IMMUNOLOGY
卷 13, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2022.833792
关键词
antigen presentation machinery; glioma; microenvironment; prognosis; genomic alteration; immunotherapy
类别
资金
- Hunan Provincial Natural Science Foundation of China [2019JJ80056, 2020YK10]
In this study, a large-scale bioinformatics analysis was conducted to explore the prognostic and predictive value of antigen presentation machinery (APM) signature in gliomas. The APM signature and risk score based on it showed promising performance in stratifying survival and predicting tumorigenic factors in glioma patients. The APM signature-based risk score was also validated in external cohorts and successfully predicted immunotherapy response. This study provides insights into the potential clinical applications of APM signature and risk score in gliomas.
Immunogenicity, influenced by tumor antigenicity and antigen presenting efficiency, critically determines the effectiveness of immune checkpoint inhibitors. The role of immunogenicity has not been fully elucidated in gliomas. In this study, a large-scale bioinformatics analysis was performed to analyze the prognostic value and predictive value of antigen presentation machinery (APM) signature in gliomas. ssGSEA algorithm was used for development of APM signature and LASSO regression analysis was used for construction of APM signature-based risk score. APM signature and risk score showed favorable performance in stratifying survival and predicting tumorigenic factors of glioma patients. APM signature and risk score were also associated with different genomic features in both training cohort TCGA and validating cohort CGGA. Furthermore, APM signature-based risk score was independently validated in three external cohorts and managed to predict immunotherapy response. A prognostic nomogram was constructed based on risk score. Risk score-derived CALR was found to mediate the invasion and polarization of macrophages based on the coculture of HMC3 and U251 cells. CALR could significantly predict immunotherapy response. In conclusion, APM signature and APM signature-based risk score could help promote the clinical management of gliomas.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据